Biotechnology company Oxford BioDynamics, Plc (AIM: OBD) announced on Wednesday that clinical validation of its EpiSwitch Prostate Screening (PSE) test has been completed at its newly commissioned ISO15189 UK clinical laboratory. The move halves the turnaround time for PSE tests ordered by UK physicians, enhancing accessibility.

The PSE test, with 94% accuracy, combines PSA scores with proprietary epigenetic biomarkers to predict prostate cancer presence. The test aids in avoiding unnecessary biopsies for low-risk cases and prompts referrals for further investigation in high-risk instances.

OBD will soon validate its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) within the UK facility, targeting immuno-oncology checkpoint inhibitor treatments. This advance bolsters OBD's precision medicine offerings, positioning it as a key player in the global biotechnology landscape.

Headquartered in Oxford, UK, Oxford BioDynamics is listed on AIM of the London Stock Exchange. With a robust technology portfolio and numerous partnerships, OBD is at the forefront of developing personalised healthcare solutions based on its proprietary EpiSwitch platform.